|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Adenomas and carcinomas showing both nuclear and reduced membranous expression of beta-catenin, compared with those with normal membranous expression, tended to show allele loss ( P<0.01).
|
11956815 |
2002 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Beta-catenin and adenomatous polyposis coli (APC) mutations in adenomas from hereditary non-polyposis colorectal cancer patients.
|
10936679 |
2000 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
LHGDN |
CTNNB1 mutations were found in 2/19 adenomas without APC mutation.
|
12737446 |
2003 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
CTNNB1 mutations were only found in two intestinal-type adenomas (4%).
|
23208952 |
2013 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
β-Catenin stained the cell membrane, cytoplasm, and nuclei of the adenoma.
|
25449630 |
2015 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A strong topographical correlation was noted between human defensin 5 expression and nuclear beta-catenin expression in conventional adenomas and in conventional dysplastic epithelium of mixed polyps.
|
19269007 |
2009 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Activating mutations in CTNNB1 in aldosterone producing adenomas.
|
26815163 |
2016 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Activation of β-catenin and ERK1/2 was mitigated in Apc(Min/+);Nherf2(-/-) adenomas.
|
26867566 |
2016 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Activation of the Wnt pathway by conditionally deleting exon 3 of the beta-catenin gene at an early stage of enteroendocrine cell differentiation induced small-intestinal adenomas expressing serotonin, a feature not previously described in other tumors induced by Wnt in mice.
|
17592150 |
2007 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Advanced traditional serrated adenomas retained MLH1 expression in 97%, showed strong p53 staining in 55%, and nuclear β-catenin staining in 40%.
|
25216220 |
2015 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Altered expression of beta-catenin, such as nuclear or cytoplasmic expression and loss of membranous expression, was also significantly higher in adenomas than in dysplasias or carcinomas (p <0.001).
|
12023580 |
2002 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Although a small subset of SLs are known to harbour TP53 mutations and Wnt/β-catenin pathway activation, suggesting that they may develop dysplasia or CRC via a 'chromosomal instability (CIN)-like' pathway, it is unclear if aneuploidy (characteristic of conventional adenoma) ever develops in SLs and is associated with development of dysplasia or CRC, in this context.
|
29772067 |
2018 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
An advanced invasive non-functioning adrenocortical carcinoma carried a somatic heterozygous BRAF V600E mutation, while 4 functioning and 4 non-functioning adenomas and 3 functioning carcinomas carried different CTNNB1 activating mutations.
|
19498322 |
2009 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
An identical CTNNB1 mutation was identified in the 1996 liver tumor together with a TERT promoter mutation showing that this hepatocellular carcinoma results from the malignant transformation of the initial β-catenin inflammatory adenoma.
|
27984126 |
2017 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
An important role for beta-catenin pathways in colorectal carcinogenesis was first suggested by the protein's association with adenomatous polyposis coli (APC) protein, and by evidence of dysregulation of beta-catenin protein expression at all stages of the adenoma-carcinoma sequence.
|
11839557 |
2002 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis.
|
11522744 |
2001 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Because alterations of the adenomatous polyposis coli (APC) gene are present in biliary tract cancers and the APC protein modulates levels of beta-catenin, we evaluated the role of beta-catenin in biliary tract cancer by sequencing the third exon of the beta-catenin gene among 107 biliary tract cancers and 7 gallbladder adenomas from a population-based study in CHINA: Point mutations of serine or threonine phosphorylation sites in exon 3 of beta-catenin were present in 8 of 107 (7.5%) biliary tract cancers and 4 of 7 (57.1%) gallbladder adenomas.
|
11309300 |
2001 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
BRAF and beta-catenin mutations were detected in 3 and 8% of the 101 flat-type adenomas, respectively.
|
17143260 |
2007 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Concurrent administration of the ROS inhibitor N-acetylcysteine abrogated β-catenin/HIF pathway activity and restored adenoma architecture.
|
23246962 |
2013 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Consistent with the presence of WNT pathway gene alterations, all superficially serrated adenomas showed focal or diffuse nuclear β-catenin accumulation.
|
29789649 |
2018 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
CXCL8 expression correlated with nuclear beta-catenin localization in epithelial cells of adenomas, but was associated with endothelial cells and neutrophils in the adenocarcinomas.
|
19173296 |
2009 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Delta ligands regulate Notch signaling in normal intestinal stem cells, while Jagged1 activates Notch in intestinal adenomas carrying active β-catenin.
|
30065304 |
2018 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Dual staining emphasized the strong interaction of β-catenin and NICD in adenoma and adenocarcinoma than in normal tissues.
|
25073953 |
2014 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Dysplastic adenomas accumulate β-catenin and lose heterozygosity of APC.
|
22864254 |
2012 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression profiling revealed that ISC signatures, as well as the Wnt/β-catenin and Notch signaling pathways are downregulated in Ap4-deficient adenomas and intestinal organoids.
|
30177706 |
2018 |